JNJ-54175446
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- JNJ-54175446
- Molecular weight
- 440.79
- Structure (SMILES)
- C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl
- jnj 54175446
- JNJ 54175446
- Jnj-54175446
- JNJ-54175446
- JNJ-54175446 (capsule)
- JNJ-54175446 150 mg
- JNJ-54175446 600 mg
- JNJ-54175446, 150 mg
- JNJ-54175446, 600 mg
- CAS registry numbers
- 1627902-21-9
- ChEMBL ID
- CHEMBL4079239
- InChIKey
- CWFVVQFVGMFTBD-SECBINFHSA-N
- PubChem compound IDs
- 90409366
- FDA ingredient codes (UNII)
- 32524GLF40
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- P2X purinoceptor 7 antagonist
- Action type
- Antagonist
- Target
- P2X purinoceptor 7
- Protein identifier
- Q99572
Open Targets mechanisms
- Mechanism
- P2X purinoceptor 7 antagonist
- Action type
- Antagonist
- Target
- P2X purinoceptor 7
Investigated indications
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 2
Trial references
- NCT02902601
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 76.8
- Calculated partition coefficient (ALogP)
- 3.63
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 30
- Molecular formula
- C18H13ClF4N6O
- Monoisotopic mass
- 440.0775494
- Natural product
- No
- Recorded assays
- 92
- Active assays
- 34
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (407)
- 12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults
- 14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man
- 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
- A 28 Day Parallel Group Study to Assess the Effects of RDN-929
- A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
- A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy
- A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)
- A Clinical Study of Gulingji Capsule in the Treatment of Idiopathic Oligospermia, Asthenia, and Teratozoospermia
- A Clinical Study of Treating Influenza With Liugan Shuangjie Heji
- A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome
- A Clinical Study of Xin'an Medicine in the Treatment of Knee Osteoarthritis
- A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)
- A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects
- A Clinical Trial of CS12192 in Healthy Subjects
- A Clinical Trial of Fecal Microbiota Transplantation in a Population With Obsessive-compulsive Disorder
- A Clinical Trial of KT07 Capsule in the U.S.A
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- A Clinical Trial of TQH3906 Capsules in Healthy Volunteers
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
In development for (1)
- Major depressive disorder Phase 1
Targets (1)
- P2RX7 P2X purinoceptor 7 antagonist